<?xml version="1.0" encoding="UTF-8"?>
<GaPExchange xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:noNamespaceSchemaLocation="./dbGaPEx2.1.5.xsd">

<MetaVariables>
	<Submitter/>
	<Method/>
</MetaVariables>
<MetaLinks/>

<Projects>
	<Project/>
</Projects>

<Studies>

<Study source="dbGaP" accession="phs001027.v1.p1" parentStudy="phs001027.v1.p1" createDate="2015-11-05" modDate="2016-03-08">

<Configuration>
	<Data_Provider><![CDATA[
		<table border="1">
		<tr><th>Title</th><th>Name</th><th>Institute</th></tr>
		<tr><td>Principal Investigator</td><td>Francine Garrett-Bakelman, MD, PhD</td><td>Weill Cornell Medical College, New York, NY, USA</td></tr>
		<tr><td>Funding Source</td><td>K08CA169055</td><td>National Cancer Institute, National Institutes of Health, Bethesda, MD, USA</td></tr>
		</table>
	]]></Data_Provider>
	<StudyNameEntrez>Epigenomics studies in Acute Myeloid Leukemia (AML)</StudyNameEntrez>
	<StudyNameReportPage>Epigenomics studies in Acute Myeloid Leukemia (AML)</StudyNameReportPage>
	<StudyTypes>
		<StudyType>Cohort</StudyType>
	</StudyTypes>
	<Description><![CDATA[
<p>Acute Myeloid Leukemia (AML) remains a clinical challenge since most patients diagnosed with AML will die from the disease. Some patients harbor treatment-refractory disease and others relapse with disease that in many cases is resistant to treatments. Our study was designed to understand the molecular basis of disease progression in AML through interrogation of patient samples collected through an international collaboration which assembled 138 paired (diagnosis and relapse) patient specimens.</p> <p>It is hoped that this resource will help researchers understand mechanisms of disease relapse in AML and contribute to the general pool of data available for analyses for this disease and general research use.</p>]]>
	</Description>
	<StudyInEx><![CDATA[
<p>Inclusion and exclusion criteria for specimens included:</p> <p>Inclusion criteria: patients diagnosed with non-M3 Acute Myeloid Leukemia (AML), who received induction chemotherapy treatment with combination chemotherapy including, but not limited to an anthracycline and cytosine arabinoside, and patients from whom specimens with high blast cell percentages were available from diagnosis and relapse time points. Age-matched controls were obtained from individuals without any known hematological conditions with CD34+ cell enrichment greater than 90%.</p> <p>Exclusion criteria: patients with M3 AML (Acute Promyelocytic Leukemia), patients who received hypothemyltaing agents during induction treatment, patients who relapsed more than five years after the original diagnosis.</p>]]>
	</StudyInEx>
	<StudyProjects>
		<Project/>
	</StudyProjects>
	<Publications>
		<Publication>
			<Pubmed pmid="25260792"/>
		</Publication>
	</Publications>
	<Diseases>
		<Disease vocab_source="MESH" vocab_term="Acute Myeloid Leukemia"/>
	</Diseases>
	<Attributions>
		<Header title="Principal Investigator">
			<AttName>Francine Garrett-Bakelman, MD, PhD</AttName>
			<Institution>Weill Cornell Medical College, New York, NY, USA</Institution>
		</Header>
		<Header title="Funding Source">
			<AttName>K08CA169055</AttName>
			<Institution>National Cancer Institute, National Institutes of Health, Bethesda, MD, USA</Institution>
		</Header>
	</Attributions>
	<DisplayPublicSummary>yes</DisplayPublicSummary>
	<StudyHistory><![CDATA[
<p>N/A - specimens were not part of a specific clinical trial</p>]]>
	</StudyHistory>
	<ConsentGroups>
		<ConsentGroup groupNum="1" shortName="GRU-PUB" longName="General Research Use (PUB)"/>
	</ConsentGroups>
</Configuration>

  <AuthorizedAccess>
    <DacInfo ssDacId="0">
      <DacName>NCI</DacName>
      <DacFullName>NCI</DacFullName>
      <DacEmail>0</DacEmail>
      <DacPhone></DacPhone>
      <DacUrl></DacUrl>
    </DacInfo>
    <Policy Policy_ID="phs001027.v1.p1_policy" ref_ssDacId="0">
      <DisplayResearchStatement>yes</DisplayResearchStatement>
      <DisplayPublicSummary>yes</DisplayPublicSummary>
      <EmbargoLength>0</EmbargoLength>
      <YearsUntilRenewal>1</YearsUntilRenewal>
      <WeeksCancelRequest>8</WeeksCancelRequest>
      <PdfSupplementReqired>no</PdfSupplementReqired>
      <AcknowledgementText>
        <para>
          http://dbgap.ncbi.nlm.nih.gov/aa/wga.cgi?page=DUC&amp;view_pdf&amp;stacc=phs001027.v1.p1
        </para>
      </AcknowledgementText>
      <DocumentSet>
        <DataUseCertificate Label="Data Use Certificate" FilePath="https://dbgap.ncbi.nlm.nih.gov/aa/wga.cgi?page=DUC&amp;view_pdf&amp;stacc=phs001027.v1.p1" FileName=""/>
      </DocumentSet>
    </Policy>
    <ConsentGroups>
      <ParticipantSet groupNum-REF="1">
        <ConsentName>General Research Use (PUB)</ConsentName>
        <ConsentAbbrev>GRU-PUB</ConsentAbbrev>
        <UseLimitation>Use of the data is limited only by the terms of the model Data Use Certification.
Requestor agrees to make results of studies using the data available to the larger scientific community.</UseLimitation>
        <IrbRequired>No</IrbRequired>
      </ParticipantSet>
    </ConsentGroups>
  </AuthorizedAccess>


</Study>

</Studies>

</GaPExchange>
